| Old Articles: <Older 6531-6540 Newer> |
|---|
 |
The Motley Fool
August 5, 2010
Brian Orelli |
Blockbuster Efficacy! Not-So-Blockbuster Safety! Isis and Genzyme's wonder drug has not-so-wonderful side effects. Still.   |
The Motley Fool
August 5, 2010
Seth Jayson |
Show Me the Money, Merck Merck turned 7% of its revenues into free cash flow. That looks pretty good, but as the chart shows, it's a lot less than in years past. |
The Motley Fool
August 4, 2010
Brian Orelli |
No Nail Yet, but Vertex Creeps Up to Merck's Coffin Merck's hepatitis C data doesn't look as good as Vertex's. |
The Motley Fool
August 4, 2010
Amanda B. Kish |
3 Big Bets on Health Care As Americans age, funds heavy in health care could really pay off. |
The Motley Fool
August 4, 2010
Matt Koppenheffer |
How Much Is Abbott Labs Worth? Is Abbott Labs' stock on sale? |
The Motley Fool
August 4, 2010
Mac Greer |
One Biotech Stock Ready to Rebound? One of our analysts gives you his thoughts on Elan. |
The Motley Fool
August 4, 2010
Rex Moore |
The 15 Best Values in Health Care Low multiples plus low risk equals compelling value. |
The Motley Fool
August 4, 2010
Luke Timmerman |
Dendreon Conference Call Notebook: The Tale of a Provenge Launch Ramp-Up What's working for Dendreon? How is its groundbreaking prostate cancer drug performing in its first few months on the market? |
The Motley Fool
August 4, 2010
Ryan McBride |
How Eli Lilly Let a Billion-Dollar Molecule Slip Away, and Make a Fortune for Vertex The remains of Lilly's partnership with Vertex Pharmaceuticals. |
The Motley Fool
August 4, 2010
Brian Orelli |
Dendreon Doubles Up The biotech enjoys twice as much revenue month over month. |
| <Older 6531-6540 Newer> Return to current articles. |
